HC Wainwright & Co. Reiterates Neutral on Summit Therapeuticsto Neutral

Benzinga Newsdesk www.benzinga.com Neutral 72.0%

Neg 0% Neu 72% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) from Neutral to Neutral.

Comments

No comments yet. Be the first!